GAMMA Investing LLC Purchases 37,735 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

GAMMA Investing LLC boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 4,151.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,644 shares of the company's stock after purchasing an additional 37,735 shares during the period. GAMMA Investing LLC owned about 0.08% of Amphastar Pharmaceuticals worth $1,120,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after buying an additional 493 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after acquiring an additional 871 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $38,000. Tower Research Capital LLC TRC raised its position in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the last quarter. Finally, Huntington National Bank raised its position in Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Down 1.4%

Shares of Amphastar Pharmaceuticals stock traded down $0.37 during trading on Tuesday, reaching $25.61. The company's stock had a trading volume of 399,985 shares, compared to its average volume of 488,899. The company has a market cap of $1.21 billion, a price-to-earnings ratio of 8.22, a PEG ratio of 6.77 and a beta of 0.77. The firm's 50-day moving average is $24.71 and its two-hundred day moving average is $30.63. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AMPH shares. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Wells Fargo & Company cut their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.